Expert Rev of Obstet Gynecol. 2010;5(6):673-686. © 2010 Expert Reviews Ltd. Each year worldwide, over 380,000 women die from pregnancy and pregnancy-related causes ...

Evidence published today on a new contraceptive option is providing one possible answer to an age-old question in family planning: how to address barriers that make it difficult for women to keep ...

Depot-medroxyprogesterone acetate is a commonly used injectable contraceptive that has been associated with an increased risk of HIV acquisition. This study compares effects of ...

A new contraceptive option provides a possible answer to an age-old question in family planning: how to address barriers that make it difficult for women to keep using contraception consistently.

The injectable contraceptive depot-medroxyprogesterone acetate (DMPA) appears to increase a woman’s risk of acquiring the sexually transmitted infections chlamydia and gonorrhea by approximately three ...

A non-governmental research organisation, Akena Plus Health, has dispelled the misconception that the Depot-Medroxyprogesterone Acetate-Sub Cutaneous, an all-in-one contraceptive that puts women in ...

Injection site reactions such as injection site pain, injection site tenderness, injection site nodules, injection site atrophy (persistent) and lipoatrophy of the injection site have been reported ...

With Gift Aid, your generous donation of £10 would be worth £12.50 at no extra cost to you. Yes, I want to Gift Aid any donations made to NAM now, in the future and in the past four years I am a UK ...

Expert Rev of Obstet Gynecol. 2010;5(6):673-686. Each year worldwide, over 380,000 women die from pregnancy and pregnancy-related causes. If contraception were made available to unprotected women, ...

Seattle, April 12, 2018--Evidence published today on a new contraceptive option is providing one possible answer to an age-old question in family planning: how to address barriers that make it ...

"This is an exciting milestone for women in the United Kingdom, and, potentially, in countries around the world, who might prefer this method of contraception and mode of administration." Pfizer Inc.